Tedroff Kristina, Granath Fredrik, Forssberg Hans, Haglund-Akerlind Yvonne
Neuropediatric Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, S-171 76 Stockholm, Sweden.
Dev Med Child Neurol. 2009 Feb;51(2):120-7. doi: 10.1111/j.1469-8749.2008.03189.x.
The long-term effects of botulinum toxin A (BoNT-A) treatment in children with cerebral palsy (CP) are still elusive. We studied a prospective clinical cohort of 94 children with different subtypes (50% spastic diplegic CP, 22% hemiplegic CP, 25% tetraplegic CP, 3% dyskinetic CP), sex (55% male, 45% female), severity according to Gross Motor Function Classification System (29% Level I, 15% Level II, 16% Level III, 17% Level IV, 23% Level V), and age (median 5y 4mo, range 11mo-17y 8mo). The longest follow-up time was 3 years 7 months (median 1y 6mo) and included a maximum of eight injections per muscle (median two injections to a specific muscle). Outcome measurements were muscle tone (Modified Ashworth Scale) and joint range of motion (ROM). Assessments were made at a minimum before and 3 months after each injection. Ninety-five per cent confidence intervals for differences from baseline were used to identify significant changes. BoNT-A injections induced reduction of long-term spasticity in all muscle-groups examined: the gastrocnemius, hamstring, and adductor muscles. The reduction in tone was most distinct in the gastrocnemius muscle, and each repeated injection produced an immediate reduction in muscle tone. However, improvement in ROM was brief and measured only after the first injections, whereupon the ROM declined. Thus, the results suggest that BoNT-A can be effective in reducing muscle tone over a longer period, but not in preventing development of contractures in spastic muscles. The dissociation between the effects on muscle tone and ROM indicates that development of contractures is not coupled to increased muscle tone only, but might be caused by other mechanisms.
A型肉毒毒素(BoNT-A)治疗脑瘫(CP)患儿的长期效果仍不明确。我们对94名不同亚型(50%痉挛性双瘫型CP、22%偏瘫型CP、25%四肢瘫型CP、3%运动障碍型CP)、性别(55%为男性,45%为女性)、根据粗大运动功能分类系统划分的严重程度(29%为I级、15%为II级、16%为III级、17%为IV级、23%为V级)以及年龄(中位数为5岁4个月,范围为11个月至17岁8个月)的患儿进行了一项前瞻性临床队列研究。最长随访时间为3年7个月(中位数为1年6个月),每个肌肉最多注射8次(特定肌肉的中位数为2次注射)。结局指标为肌张力(改良Ashworth量表)和关节活动范围(ROM)。每次注射前至少进行一次评估,并在注射后3个月进行评估。采用与基线差异的95%置信区间来确定显著变化。BoNT-A注射可使所有检查的肌肉群(腓肠肌、腘绳肌和内收肌)的长期痉挛减轻。腓肠肌的肌张力降低最为明显,每次重复注射都会使肌张力立即降低。然而,ROM的改善是短暂的,仅在首次注射后进行测量,随后ROM下降。因此,结果表明BoNT-A在较长时间内可有效降低肌张力,但不能预防痉挛性肌肉挛缩的发展。肌张力和ROM的影响之间的分离表明,挛缩的发展不仅与肌张力增加有关,还可能由其他机制引起。